BSE Live
Apr 17, 16:01Prev. Close
69.05
Open Price
68.50
Bid Price (Qty.)
68.00 (25)
Offer Price (Qty.)
68.75 (5)
NSE Live
Apr 17, 15:56Prev. Close
69.57
Open Price
68.55
Bid Price (Qty.)
68.82 (120)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Alpa Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 111.63 | 107.92 | 92.41 | 110.51 | 96.41 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 111.63 | 107.92 | 92.41 | 110.51 | 96.41 | |
| Total Operating Revenues | 112.45 | 108.74 | 92.96 | 112.27 | 97.55 | |
| Other Income | 23.31 | 14.87 | 9.41 | 10.79 | 4.41 | |
| Total Revenue | 135.76 | 123.61 | 102.36 | 123.06 | 101.96 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 70.72 | 62.88 | 52.45 | 63.42 | 54.23 | |
| Purchase Of Stock-In Trade | 0.93 | 5.80 | 1.22 | 5.82 | 6.39 | |
| Operating And Direct Expenses | 5.85 | 6.57 | 6.55 | 6.31 | 5.29 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -1.45 | -0.64 | 1.27 | 0.53 | -1.15 | |
| Employee Benefit Expenses | 14.37 | 13.26 | 12.17 | 11.93 | 11.75 | |
| Finance Costs | 0.27 | 0.39 | 0.22 | 0.24 | 0.10 | |
| Depreciation And Amortisation Expenses | 2.20 | 1.95 | 1.33 | 1.66 | 1.23 | |
| Other Expenses | 17.04 | 12.73 | 11.21 | 13.56 | 13.34 | |
| Total Expenses | 109.92 | 102.94 | 86.43 | 103.48 | 91.17 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 25.84 | 20.67 | 15.93 | 19.58 | 10.79 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 25.84 | 20.67 | 15.93 | 19.58 | 10.79 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 4.06 | 3.78 | 3.60 | 3.10 | 2.50 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 2.10 | 0.11 | -0.29 | 2.35 | 1.14 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | -0.11 | |
| Total Tax Expenses | 6.16 | 3.90 | 3.31 | 5.45 | 3.53 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 19.68 | 16.78 | 12.62 | 14.13 | 7.26 | |
| Profit/Loss From Continuing Operations | 19.68 | 16.78 | 12.62 | 14.13 | 7.26 | |
| Profit/Loss For The Period | 19.68 | 16.78 | 12.62 | 14.13 | 7.26 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 9.42 | 8.01 | 5.90 | 6.71 | 3.46 | |
| Diluted EPS (Rs.) | 9.42 | 8.01 | 5.90 | 6.71 | 3.46 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
25.02.2026
Alpa Labs Consolidated December 2025 Net Sales at Rs 29.05 crore, up 11.07% Y-o-Y
25.02.2026
Alpa Labs Standalone December 2025 Net Sales at Rs 29.67 crore, up 13.46% Y-o-Y
04.12.2025
Alpa Labs Consolidated September 2025 Net Sales at Rs 26.26 crore, up 5.29% Y-o-Y
27.11.2025
Alpa Labs Standalone September 2025 Net Sales at Rs 25.63 crore, up 2.78% Y-o-Y
25.02.2026
Alpa Labs Consolidated December 2025 Net Sales at Rs 29.05 crore, up 11.07% Y-o-Y
25.02.2026
Alpa Labs Standalone December 2025 Net Sales at Rs 29.67 crore, up 13.46% Y-o-Y
04.12.2025
Alpa Labs Consolidated September 2025 Net Sales at Rs 26.26 crore, up 5.29% Y-o-Y
27.11.2025
Alpa Labs Standalone September 2025 Net Sales at Rs 25.63 crore, up 2.78% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth